A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Interventions:   Drug: Vosaroxin;   Drug: Azacitidine Sponsors:   University of Ulm;   Sunesis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials